News

PD-L1 blockade breaks through triple-negative breast cancer


 

FROM THE AACR ANNUAL MEETING

References

Earlier in the meeting, stellar results with the checkpoint inhibitor pembrolizumab from the KEYNOTE-006 trial upended the treatment paradigm for advanced melanoma. Pembrolizumab has been evaluated in TNBC and the safety profile and responses are similar to those with MPDL3280A, Dr. Emens said.

A global phase III trial evaluating MPDL3280A in combination with paclitaxel (Abraxane) as first-line therapy for metastatic TNBC is preparing to launch.

pwendling@frontlinemedcom.com

On Twitter @pwendl

Next Article: